2425 55th Street, Suite 210 Boulder, CO 80301 303-420-4420

Empowering proteins to better treat diseases

Our diversified product pipeline includes treatments for hematological and endocrine disorders, cancer and infectious diseases. We intend to commercialize these products independently and through strategic alliances with corporate partners.

Technology

We use two protein engineering technologies, Site-Specific PEGylation and ImmunoFusion Protein technology to create our proprietary products. Both technologies increase a protein's effective size and slow its clearance from the body.
Read more

 

Pipeline

Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer and infectious disease.
Read more

BioDefense

The U.S. government is actively supporting identification and development of drugs to prevent or treat the complications of acute, high dose radiation exposure,such as might occur following a nuclear power plant accident or detonation of a nuclear weapon.
Read more

News

NIAID Exercises Option to Continue Preclinical Development of Bolder BioTechnology’s BBT-059 IL-11 Analog to Treat Acute Radiation Syndrome

Boulder, Colorado – November 18, 2024 - Bolder BioTechnology, Inc. announced today that the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to fund…

read more
Bolder BioTechnology Announces Positive Preclinical Data for Use of BBT-032 to Inhibit Growth of the SARS-CoV-2 Virus

Boulder, Colorado – August 25, 2020 - Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus…

read more
Bolder BioTechnology Announces Scientific Presentations at the 2019 Radiation Research Society Annual Meeting

Boulder, Colorado – November 7, 2019 - Bolder BioTechnology is pleased to announce that three scientific presentations describing use of the company’s novel interleukin-11 analog BBT-059 to treat acute radiation syndrome were…

read more
Bolder BioTechnology Receives NIH Grant to Advance Development of Novel Treatments for Acute Radiation Syndrome

Boulder, Colorado – July 18, 2019 - Bolder BioTechnology, Inc. announced today that it has been awarded a two year Small Business Innovation Research Grant totaling $593,507 from the National Institute of…

read more
Bolder BioTechnology Announces FDA Orphan Drug Designation for BBT-059 for Acute Radiation Syndrome

Boulder, Colorado – June 12, 2019- Bolder BioTechnology, Inc. announced today that its long-acting IL-11 analog, BBT-059, has received Orphan Drug designation from the Food and Drug Administration for treatment of Acute…

read more
Bolder BioTechnology to Present Preclinical Data for Three Research Programs at Acute Radiation Syndrome Meeting

Boulder, Colorado – October 24, 2018- Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, will give an oral presentation at the “A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome…

read more
Bolder BioTechnology Announces Presentation at Radiation Injury Treatment Conference

Boulder, Colorado – September 6, 2018 – Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, gave an oral presentation at the “Growth Factors and Other Cytokines for Treatment of…

read more
Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers

Boulder, Colorado – April 27, 2018- Bolder BioTechnology, Inc. announced today that it has completed a Phase 1 clinical trial of BBT-015, a proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, in healthy…

read more